AmniSure International LLC declared victory in its seven-year patent fight with a Finnish company.
The High Court of Germany voided the Medix Biochemica patent associated with that firm’s Actim PROM test for detection of premature rupture of fetal membranes, according to AmniSure. The court ruled that Medix’s patent lacked a so-called "inventive step," meaning it is too closely related to previously patented technology.
Boston-based AmniSure is expecting Medix to pay it a yet-to-be-determined amount, which will be decided by the German court, according to a press release.
AmniSure also touted the results of an article published in Guidelines of the European Association of Perinatal Medicine that called its PROM test the “most useful tool” and the “most accurate bedside test” for diagnosing ruptured fetal membranes.
"The publication of the European Guidelines … opens a new chapter for us by establishing the AmniSure test as the new benchmark for diagnosing ruptured fetal membranes," CEO Michael Friedman said in prepared remarks.